Latest news
17 Mar, 2021 · In Press Releases
17 Mar, 2021 · In Press Releases
Bioservo develops the next generation of rehabilitative gloves
World’s first soft robotic muscle strengthening system. Developed in collaboration with leading Fortune 500 companies
Master of Science in Business Administration and Economics from the Uppsala University. Has 25 years of experience as CFO alongside with growth related operational responsibilities. He has been working under private equity regimes as well as in both listed and privately held companies, e.g CFO assignments at the Phadia group, 2005-2011, as well as Iggesund Paperboard, Trelleborg Industries and Observer/Cision. Today he is the Chairman of Tellacq AB and Bioservo Technologies AB and member of the Board of Antrad Medical, Motion Display and Secure Appbox.
Dependent in relation to the company's major owners.
Entry: 2016
Holding: 1 526 000 shares as well as 1 600 warrants
Master of Science in Business from Lund University, Sweden. Background in accounting at various accounting firms. CFO at Nycomed Pharma AS from 1997 until 2011. Currently, Runar is COB of ConceptoMed AS, a Norwegian MedTech Company and is Board member of Bioservo Technologies AB, Norsk Kjededrift AS, SE Holding AS and acts as a consultant and member of the Audit Committee of Acino, a Swiss Pharmaceutical Company.
Dependent in relation to the company's major owners.
Entry: 2016
Holding: 1 600 warrants
BA/MA in Economics from Cambridge University and MBA in Finance from the Wharton School at the University of Pennsylvania. Kunal is a healthcare-focused private equity investor, with experience of investing in small and mid-cap companies across Europe and North America. He has worked previously at Avista Capital Partners, DLJ Merchant Banking Partners and Lehman Brothers. He is currently a Board member of Nordic BioSite, Acino International and Trimb Healthcare, and was previously a Board member of ConvaTec and Guala Closures.
Dependent of the company's major owners.
Entry: 2018
Nikolaj Sørensen
Master of Science in Economics from the Stockholm School of Economics as well as the Copenhagen Business School. Nikolaj is currently President and CEO of Orexo AB, a publicly Swedish specialty pharmaceutical company. Nikolaj has been CEO of Orexo AB since 2013 and has contributed to the establishment of Orexo in the US and the transformation of Orexo from development companies to a company in a commercial phase. Before Orexo, he has worked many years in senior positions and as an advisor in life science in Sweden and internationally.
Independent.
Entry: 2019
Holding: 15 100 shares
Claes Mellgren
Claes Mellgren founder of the AQ Group, a global manufacturer of components and systems for industrial customers, was also CEO for the company between the years 2010 and 2018. He has previously been production, logistics and site manager at different ABB units in Västerås. Claes is today mainly working as an angel-investor and has several board positions including AQ Group (Nasdaq Mid Cap), Note AB (Nasdaq Small Cap) and Automation Region. Claes has a Master of Science degree from the University of Linköping.
Independent.
Entry: 2020
Holding: 95 568 shares
